Johnson & Johnson (JNJ)

142.66
0.61 0.43
NYSE : Health Technology
Prev Close 143.27
Open 142.76
Day Low/High 140.58 / 144.43
52 Wk Low/High 109.16 / 157.00
Volume 3.03M
Avg Volume 7.98M
Exchange NYSE
Shares Outstanding 2.63B
Market Cap 376.35B
EPS 5.70
P/E Ratio 22.31
Div & Yield 4.04 (2.70%)

Cramer: The Money Will Flow to the Best International Stories

Let's go over what allows us to get to highs for the year.

Jim Cramer Is Watching Janet Yellen's Speech Early Next Week

Jim Cramer Is Watching Janet Yellen's Speech Early Next Week

Federal Reserve Chair Janet Yellen should say the Fed can't raise interest rates right now when she speaks in Philadelphia on Monday, according to Jim Cramer.

Cramer: Many Portfolio Managers Hope for the 'Wrong' Jobs Number

Cramer: Many Portfolio Managers Hope for the 'Wrong' Jobs Number

This is because they would buy more of the winning stocks lower.

Cramer: These Voices Say Not to Give Up on This Market

Cramer: These Voices Say Not to Give Up on This Market

Do the homework and you'll find great stocks.

Jim Cramer Likes Johnson and Johnson Hair Care Deal

Jim Cramer Likes Johnson and Johnson Hair Care Deal

Jim Cramer says he likes Johnson & Johnson's purchase of privately-held hair care products maker Vogue International.

Opening Bell: U.S. Stocks Slip as ECB Keeps Rates Unchanged; OPEC Fails to Reach Production Freeze

Opening Bell: U.S. Stocks Slip as ECB Keeps Rates Unchanged; OPEC Fails to Reach Production Freeze

U.S. stocks opened slightly lower on Thursday, as investors parsed commentary from European Central Bank President Mario Draghi, following its June policy meeting.

3 Small Biotechs That Look Very Healthy

Peter Lynch and other market legends would love these names.

Cramer: Dow Components, Part 2 -- A Whole Lot of Nothing

Cramer: Dow Components, Part 2 -- A Whole Lot of Nothing

Many familiar names, but are any worth buying?

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Coming off a brutal first quarter, Bill Ackman's hedge fund announced the loss of a key strategist.

Sizing Up Johnson & Johnson's Talcum Fallout

Sizing Up Johnson & Johnson's Talcum Fallout

The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.

The Secret Sauce to Investment Returns

The Secret Sauce to Investment Returns

Think of what dividends can do.

Jim Cramer: Smart Money on Wall Street Turning to Consumer Goods

Jim Cramer: Smart Money on Wall Street Turning to Consumer Goods

There is an overall flow of funds out of the stock market after a weak jobs report.

Cramer: Market Rotation Is Happening Ahead of Friday Jobs Report

Cramer: Market Rotation Is Happening Ahead of Friday Jobs Report

Investors are going to rotate back into safety stocks if the April jobs number disappoints on Friday, says TheStreet's Jim Cramer.

Cramer: What Makes a Good Stock? Read Facebook's Story

Cramer: What Makes a Good Stock? Read Facebook's Story

It has pivoted from desktop dinosaur to mobile monster in no time flat.

Jim Cramer Says Investors Should Consider Adding Drug Stocks

Jim Cramer Says Investors Should Consider Adding Drug Stocks

Jim Cramer believes the pharmaceutical sector has come full circle and some of the best stocks in the group are ready to move higher.

JNJ Investor Mtg.

Cramer: I Want to Take the Other Side of the Strong Yen Trade

Why sell companies that will benefit from a weaker dollar?

Closing Bell: S&P Removes Exxon's AAA Credit Rating; U.S. Stocks Mixed

Closing Bell: S&P Removes Exxon's AAA Credit Rating; U.S. Stocks Mixed

U.S. stocks remained mixed through the afternoon on Tuesday.

Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One

Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One

Everything about the CEO's move to Valeant stinks.

Johnson & Johnson numbers raised at BMO

What's Next for Stocks? Look at Fiscal Flows for Guidance

All this time I've been bullish because fiscal flows told me to be.

Johnson & Johnson Doesn't Need a Band-Aid

Johnson & Johnson Doesn't Need a Band-Aid

Look for JNJ to trade higher, but a close below $107 will turn the picture to bearish from bullish. 

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer says it you are going to own a drug stock, invest in Allergan or Johnson & Johnson.

Jim Cramer Says Worldwide Drug Sales Are Driving J&J’s Business

Jim Cramer Says Worldwide Drug Sales Are Driving J&J’s Business

Jim Cramer says J&J's latest quarterly report highlights strong sales of prescription drugs globally.

U.S. Stocks Rise as Oil Gains Steam; Netflix Shares Sink

U.S. Stocks Rise as Oil Gains Steam; Netflix Shares Sink

The rally continues. U.S. stocks moved higher on Tuesday, following Monday's gains.

What's Ahead Tuesday: Will Investors Get Clarity on Yahoo!'s Future?

What's Ahead Tuesday: Will Investors Get Clarity on Yahoo!'s Future?

In 'What's Ahead on Wall Street' for Tuesday April 19, the day is packed with earnings reports.

Jim Cramer Is Watching Johnson & Johnson’s Earnings on Tuesday

Jim Cramer Is Watching Johnson & Johnson’s Earnings on Tuesday

Jim Cramer awaits quarterly results from Johnson & Johnson, released before the bell on Tuesday.

It's Just an Uptrend, Don't Overthink It

The easiest way to get in trouble in the market is not to embrace the obvious.

Rally Still Has Legs for a Run Higher

Rally Still Has Legs for a Run Higher

A few charts point out why it's necessary to have a bullish stance despite how far stocks have moved already.